Form 8-K · Current Report · Filed 2025-08-27
Agilent Reports Strong Q3 2025 Financial Results with Revenue Growth and EPS Increase
Agilent Technologies, Inc. reported a strong third quarter for fiscal year 2025, with total revenue of $1.74 billion, marking a 10.1% increase year-over-year and exceeding prior guidance. The company reported GAAP net income of $336 million, or $1.18 per share, and non-GAAP net income of $390 million, or $1.37 per share, both showing increases compared to the same period in 2024. Agilent also raised its full-year revenue outlook to a range of $6.91 billion to $6.93 billion, with non-GAAP EPS expected between $5.56 and $5.59.
- Filer
- Agilent Technologies Inc. A · NYSE
- Filed
- Accession
- 0001090872-25-000034
- CIK
- 0001090872
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$118.30
Next session
+5.6%
Since filing
+17.0%
Latest close
$138.37
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from A reporting the same item, with the next session's move:
About Agilent Technologies Inc.
Agilent Technologies Inc. is a global leader in the development and provision of life sciences, diagnostics, and applied chemical markets. Primarily focused on delivering superior analytical instruments, software, services, consumables, and reagents, the company plays a critical role in supporting the research needs of pharmaceutical, biotechnology, and government laboratories. Agilent's robust portfolio includes innovative solutions for genomics, proteomics, and metabolomics, aiding in critical areas such as disease research, food safety, and environmental analysis. Established in 1999 as a spin-off from Hewlett-Packard, the company leverages its heritage of technological innovation to enhance analytical capabilities for its clients. Agilent's significant contributions to health and safety applications underscore its importance in advancing scientific understanding and supporting public health initiatives worldwide.
Never miss another A filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.